McDermott and Bull executive Search
 

Other News

Ultromics obtains Breakthrough Device FDA clearance for its Cardiac Amyloidosis screening device through the Total Product Lifecycle Advisory Program

EchoGo® Amyloidosis is an AI-based software-only medical device, which aims to improve early detection of Cardiac Amyloidosis, an underdiagnosed cause of heart failure. EchoGo® Amyloidosis sits on Ultromics’ EchoGo® platform complementing the existing commercialized EchoGo® Heart Failure…

Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System

ST. LOUIS, Nov. 20, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at the Hospital da Luz in Lisbon, Portugal have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System.

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH

— Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg monotherapy at day 84 with statistical significance (p

NeuroVascular Quality Initiative Quality Outcomes Database (NVQI-QOD) Celebrates 25,000th Procedure Milestone

NeuroVascular Quality Initiative Quality Outcomes Database (NVQI-QOD) Celebrates 25,000th Procedure Milestone FAIRFAX, Va.– The Society of NeuroInterventional Surgery’s (SNIS) Patient Safety Organization (PSO), in partnership with the NeuroPoint Alliance (NPA), is pleased to announce that the NVQI-QOD has recorded more […]